Headzol (Zolmitriptan)

Headzol is indicated for the acute treatment of migraine attacks in adults.

• Treatment of a single migraine episode when oral therapy is appropriate.
• Relief of migraine‑associated headache pain, nausea, and photophobia.
• Use as a second‑line option when non‑triptan analgesics are insufficient.
• Administration at the first sign of migraine to improve response.
• May be considered for patients with moderate to severe migraine attacks who have no contraindications to triptans.

The side‑effect profile of Headzol reflects the typical experience with oral zolmitriptan.

Common

• Tingling or numbness (paresthesia) in the face or extremities.
• Flushing or warmth sensation.
• Dizziness or light‑headed feeling.
• Nausea or mild stomach upset.
• Neck or shoulder tightness.
• Dry mouth.
• Fatigue.

Serious

• Chest pain or pressure suggestive of cardiac ischemia.
• Severe or prolonged headache not relieved by medication.
• Sudden visual disturbances or loss of vision.
• Allergic reactions such as rash, swelling, or difficulty breathing.
• Serotonin syndrome when combined with serotonergic agents.
• Severe abdominal pain.
• Unusual bleeding or bruising.

Before prescribing Headzol, clinicians should evaluate several precautionary factors to ensure safe use.

• History of cardiovascular disease, including coronary artery disease, stroke, or uncontrolled hypertension.
• Presence of peripheral vascular disorders or vasospastic conditions such as Raynaud’s phenomenon.
• Known hypersensitivity to zolmitriptan or any triptan components.
• Caution in individuals taking monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs.
• Pregnancy and breastfeeding status should be assessed, as safety data are limited.
• Evaluate for potential drug‑induced serotonin syndrome when multiple serotonergic agents are used.

Headzol can interact with other medications, affecting its efficacy or safety profile.

Avoid

• Concomitant use with other triptans or ergotamine derivatives, which may increase risk of vasospasm.
• Combined therapy with monoamine oxidase inhibitors (MAOIs) within 14 days.
• Use with selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs) that may precipitate serotonin syndrome.
• Co‑administration with potent CYP1A2 inhibitors (e.g., fluvoxamine) that can raise zolmitriptan levels.

Use with caution

• Concurrent use of other serotonergic agents such as tramadol or triptans for other indications.
• Patients on antihypertensive medications, as additive vasoconstrictive effects may occur.
• Individuals receiving dihydroergotamine or other vasoconstrictors.
• Use with caution in patients taking oral contraceptives that may affect drug metabolism.